SEC Form 20-F filed by GENFIT S.A.
$GNFT
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Unavailable
Unavailable
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/19/2025 | $9.00 | Buy | H.C. Wainwright |
| 12/20/2021 | $8.00 | Neutral → Buy | HC Wainwright & Co. |
| 9/30/2021 | $8.00 → $7.00 | Neutral | HC Wainwright & Co. |
H.C. Wainwright resumed coverage of Genfit with a rating of Buy and set a new price target of $9.00
HC Wainwright & Co. upgraded Genfit from Neutral to Buy and set a new price target of $8.00
HC Wainwright & Co. reiterated coverage of Genfit with a rating of Neutral and set a new price target of $7.00 from $8.00 previously
6-K - Genfit S.A. (0001757064) (Filer)
6-K - Genfit S.A. (0001757064) (Filer)
6-K - Genfit S.A. (0001757064) (Filer)
Seal Rock eligible to receive payments up to €100 million, including regulatory, clinical, and commercial milestone payments, plus tiered royalties SEATTLE, May 31, 2023 /PRNewswire/ -- Seal Rock Therapeutics, Inc., a clinical stage company developing first-in-class and best-in-class kinase inhibitors, today announced it has entered into an out-licensing agreement with GENFIT (Nasdaq and Euronext: GNFT) for the development of an injectable formulation of SRT-015 for acute liver disease, including Acute-on-Chronic Liver Failure (ACLF). Under the agreement, Seal Rock Therapeutic
Agreement gives Ipsen global* rights to develop and commercialize GENFIT's late-stage, first-in-class PPAR alpha and delta agonist elafibranor in Primary Biliary Cholangitis (PBC) Investigational treatment elafibranor being evaluated in the global Phase III trial, ELATIVE™, with topline data expected early 2023 GENFIT receives €120m upfront and is eligible to receive up to €360m in milestone payments as well as tiered double-digit royalties of up to 20% Ipsen becomes 8% shareholder of GENFIT via an equity investment of €28m Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211216006159/en/ Disclaimer: Inten
Agreement gives Ipsen global* rights to develop and commercialize GENFIT's late-stage, first-in-class PPAR alpha and delta agonist elafibranor in Primary Biliary Cholangitis (PBC) Investigational treatment elafibranor being evaluated in the global Phase III trial, ELATIVE™, with topline data expected early 2023 GENFIT receives €120m upfront and is eligible to receive up to €360m in milestone payments as well as tiered double-digit royalties of up to 20% Ipsen becomes 8% shareholder of GENFIT via an equity investment of €28m Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211216006159/en/ Disclaimer: Inten
SC 13G/A - Genfit S.A. (0001757064) (Subject)
SC 13G - Genfit S.A. (0001757064) (Subject)
SC 13G/A - Genfit S.A. (0001757064) (Subject)